focus -WSS

focus

author：explore 2025-09-30 20:19:59 - browse：56293

Peter Marks. -- health coverage from STAT — Peter Marks, Director of the Center for Biologics Evaluation and Research at the Food and Drug Administration. Susan Walsh-Pool/Getty Images

Peter Marks wants drug developers to ask more stupid questions.

It’s part of the top Food and Drug Administration official’s plan to reinvigorate gene therapy, a field that has struggled despite significant technological advances. Some companies are shelving programs or going out of business, even when they have promising data.

The problems are numerous: The diseases are often exceptionally rare, limiting the potential market. Manufacturing at commercial quality is complex and expensive. Proving a drug works can be difficult, because there may be too few patients to run a traditional randomized study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： As demand for Covid shots wanes, Moderna seeks its next success

WSS

Covid isolation guidance eased by the CDC

House looks to weaken Medicare negotiation

Clinical trials giant ICON acquires HumanFirst

An inside look at PIPEs, biotech's buzzy new financing tool

Kenai launches with $82 million for Parkinson’s stem cell therapy

In age of alternative facts, a scholarly course on calling out crap

entertainment

focus

knowledge

Medical records are filled with copy

Trump demands the U.S. pay no more for drugs than other countries … again

Supreme Court strikes down use of affirmative action

As demand for Covid shots wanes, Moderna seeks its next success

At least 13 dead in Texas as scorching temps continue

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Affirmative action in medical school literally saved lives

Sports medicine is finally prioritizing gender equality

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Change Healthcare cyberattack outage could last weeks

leisure time

FDA approval of Sarepta Duchenne genetic therapy gives me hope

House looks to weaken Medicare negotiation

A Q&A with Aletha Maybank, AMA’s chief health equity officer

An inside look at PIPEs, biotech's buzzy new financing tool

RSV vaccines may be linked to small increased risk of developing GBS

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

hotspot

hotspot

Wikipedia

leisure time